Singularity Hub

For 40 years, a family of proteins responsible for fueling some of the deadliest cancers has had one thing going for it: no drug could touch it.

The proteins have smooth, featureless surfaces. Nothing for a drug to grip. Researchers knew exactly what they were dealing with and couldn't do anything about it. They called them "undruggable."

A new drug just reported results in a clinical trial for advanced pancreatic cancer that stopped researchers in their tracks. Patients who had already exhausted other treatments lived significantly longer on the new drug than on chemotherapy — with less pain and fewer side effects.

It works by refusing to fight the protein directly. Instead, it targets something else entirely — and shuts the protein down from the side.
RAS isn't the only undruggable protein in oncology's crosshairs. Two others, long considered untouchable, are now being approached the same way. And AI is starting to do in days what used to take years.

What changes when "undruggable" stops being a permanent diagnosis?
Read the full story, link in comments.

Between one third and one half of patients stop taking cholesterol-lowering medications within a year — even after a heart attack.
That single statistic explains why researchers are so excited about what was just published in the New England Journal of Medicine.

A small trial of 35 patients tested a one-time gene-editing infusion that targets the root cause of high LDL cholesterol directly in the liver. The results at the highest dose were significant. In a subgroup treated 18 months ago, the effect has held.

It is unusual for the New England Journal of Medicine to publish an interim result this early. The editor in chief acknowledged as much — and published it anyway.

Cardiovascular disease kills nearly 800,000 Americans a year. Most gene therapies target rare conditions affecting thousands. This one is aimed at one of the leading causes of death on the planet — and the company behind it says they're not going for a multimillion-dollar price tag. They're going for primary care.

The researchers are clear: much more safety data is needed, and FDA guidelines require 15 years of follow-up for all gene therapy participants. But for patients who have run out of options, the early signal is hard to ignore.

Read the full story, link in comments.